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Abstract. Accurate and cost-effective identification of areas where co-endemic infections occur would enable public
health managers to identify opportunities for implementation of integrated control programs. Dried blood spots collected
during cross-sectional lymphatic filariasis surveys in coastal Kenya were used for exploratory integrated detection of IgG
antibodies against antigens from several parasitic infections (Wuchereria bancrofti, Schistosoma mansoni, Plasmodium
spp.,Ascaris lumbricoides, andStrongyloides stercoralis) aswell as for detectionof responses to immunizing agents used
against vaccine-preventable diseases (VPDs) (measles, diphtheria, and tetanus) using a multiplex bead assay (MBA)
platform. High heterogeneity was observed in antibody responses by pathogen and antigen across the sentinel sites.
Antibody seroprevalence against filarial antigens were generally higher in Ndau Island (P < 0.0001), which also had the
highest prevalence of filarial antigenemia compared with other communities. Antibody responses to the Plasmodium
species antigens circumsporozoite protein (CSP) and merozoite surface protein-1 (MSP-1)19 were higher in Kilifi and
Kwale counties, with Jaribuni community showing higher overall mean seroprevalence (P < 0.0001). Kimorigo community
in Taita–Taveta County was the only areawhere antibody responses againstS.mansoniSm25 recombinant antigenwere
detected. Seroprevalence rates to Strongyloides antigen NIE ranged between 3% and 26%, and there was high het-
erogeneity in immune responses against an Ascaris antigen among the study communities. Differences were observed
betweencommunities in termsof seroprevalence toVPDs.Seroprotection to tetanuswasgenerally lower inKwaleCounty
than in other counties. This study has demonstrated that MBA holds promise for rapid integrated monitoring of trends of
infections of public health importance in endemic areas.
INTRODUCTION
Several major infectious diseases occur in sub-Saharan
Africa includingmalaria andneglected tropical diseases (NTDs),
which are particularly common among resource-poor
populations.1–3 Consequently, several of these diseases are
co-endemic and past studies in the region have identified
subgroups that are polyparasitized with soil-transmitted hel-
minth (STH) infections, filarial parasites, and malaria.4–6 Lym-
phatic filariasis (LF) caused by Wuchereria bancrofti is
principally confined to the coastal region of Kenya where eco-
logical factors are suitable for its transmission7; the disease co-
occurs with other infectious diseases such as STH infections,
schistosomiasis, lower respiratory infections, and malaria.8–10
In the past, lack of resources often compounded by com-
peting health priorities in sub-Saharan Africa has led to
insufficient commitments to control NTDs. More recently,
however, implementation of successful public–private part-
nerships for health have availed resources for control and/or
elimination of NTDs as public health problems. In 2000, the
WHO Global Programme to Eliminate Lymphatic Filariasis
(GPELF), launched in response to World Health Assembly res-
olution WHA50.29, urged member states to initiate activities to
eliminate LF as a public health problem, a goal subsequently
targeted for 2020.11Community-widemassdrugadministration
(MDA) of antifilarial drugs for 4–6 years is recommended for LF
elimination, and modeling studies have estimated adequate
treatment coverage to be at least 65% of total population in
endemic areas.12,13 Substantial progress has been made to-
ward elimination of LF, with Togo being the first country in sub-
Saharan Africa to be recognized by theWHO for eliminating the
disease as a public health problem.14,15 The KenyanMinistry of
Health launched an LF elimination program in 2002, but the
program did not sustain MDA campaigns annually as per
GPELF recommendations.16,17 In 2015, the Ministry of Health
successfully appealed to the WHO Regional Office for Africa
and other partners for support to reestablish annual MDA
campaigns. Subsequently, the WHO Country Office in Nairobi,
Kenya, selected the Eastern and Southern Africa Centre of In-
ternational Parasitic Control (ESACIPAC), which is part of the
Kenya Medical Research Institute (KEMRI), to conduct a com-
prehensive epidemiological assessment of LF infection before
restarting MDA.
Antibody levels can provide valuable information about
exposure to infections and, thus, can be helpful for charac-
terizing pathogen transmission dynamics.18 Because parasite
antigens are generally known to elicit an IgG response that can
be detected for a long period of time, serological analysis of
young children could provide an estimate of more recent
exposure.19,20 A state-of-the-art multiplex bead assay (MBA)
serological platform that enables simultaneous detection of
antibodies against multiple antigens using a small volume of
blood sample dried on filter paper (10 μL dried blood spots
[DBS]) has been developed as a tool for integrated biomarker
surveys.21–23 The MBA has successfully been used to simul-
taneously measure antibody responses to multiple parasitic
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diseases of public health importance as part of a vaccine-
preventable disease (VPD) serological survey in Cambodia.24
The platform has also been used to simultaneously assess
IgG responses to a panel of malaria antigens.25,26 In the pre-
sent study, the MBA platform was used for multiplex seros-
urveillance of diseases of public health importance by testing
for antibodies against LF and several other parasitic diseases
(malaria, schistosomiasis, ascariasis, and strongyloidiasis) as
well as seroprevalence to selected VPDs (measles, diphtheria,
and tetanus).
MATERIALS AND METHODS
Study design and samples. The DBS samples used in this
study were collected during cross-sectional LF surveys con-
ducted in October 2015 in 10 sentinel sites located across the
coastal region in Taita–Taveta, Kwale, Kilifi, Tana River, and
Lamu counties. Counties are devolved subnational govern-
ments which relate with the national government as distinct
administrative units. In this study, a sentinel site is defined as a
rural community (village) from which data collection was
conducted with the intention of follow-up testing for moni-
toring and evaluation of the LF elimination program. A detailed
description of the 10 sentinel sites and characteristics of the
study participants were provided in an earlier report.17 Briefly,
300 persons aged 2 years or older in each sentinel site were
targeted for the LF survey as recommended in the WHO
guidelines.11 The middle finger of consenting individuals was
cleaned using a cotton ball soaked in 70% isopropyl alcohol.
After drying, the tip of the finger was pricked using a sterile
lancet and blood was collected into capillary tubes for de-
tection of circulating filarial antigen (CFA) by immunochro-
matographic card test (ICT). Additional blood sample from
the same prick site was collected onto a filter paper with six
extensions, each calibrated to absorb 10 μL volume (TropBio
Pty Ltd., Queensland, Australia), and then allowed to air-dry
for ³ 4 hours.
Recombinant antigens and coupling to microsphere
beads. Recombinant Schistosoma mansoni glutathione-S-
transferase (GST) protein was expressed from pGEX 4T-2
plasmid (GE Healthcare, Piscataway, NJ) and purified as
previously described.27 Glutathione-S-transferase fusion
proteins that included protein sequences from Brugia malayi
(Bm3322 and Bm1420), Strongyloides stercoralis (NIE28), and
Plasmodium falciparum 3D7 strain (MSP119
29) were expressed
and purified as previously described. A W. bancrofti Wb123-
GST fusion protein was a kind gift from T. Nutman (NIH,
Bethesda, MD). These proteins were coupled to SeroMap
beads (Luminex Corp., Austin, TX) using the protein quantities
and buffer conditions previously described.24 Schistosoma
mansoni–native soluble egg antigen (SEA) was a kind gift of E.
Secor (CDC, Atlanta, GA), and recombinant S. mansoni Sm25
antigen was expressed using the Baculovirus system pre-
viously described.30 Both proteins were coupled to SeroMap
beads using the protein quantities and buffer conditions pre-
viously described.30
Tetanus toxoid (Massachusetts Biological Laboratories,
Boston, MA), diphtheria toxoid from Corynebacterium diph-
theriae (List Biological Laboratories, Campbell, CA), and
recombinant measles nucleoprotein (MV-N, Meridian Life
Sciences, Memphis, TN)31 were purchased from commercial
sources. Tetanus toxoid was coupled to SeroMap beads as
previously described.32 Diphtheria toxoid was coupled in
buffer containing 50 mM 2-(N-morpholinoethanesulfonic acid
(MES) at pH5.0with 0.85%NaCl at a concentration of 60μgof
protein per 1.25 × 107 beads in 1mL final volume. To decrease
background reactivity, measles MV-N was purified by chro-
matography on a MonoQ HR 5/5 strong anion exchange col-
umn (GEHealthcare) before use. Protein (0.75mg) was loaded
onto the column at a flow rate of 1mL/minute andwashedwith
4 mL of 25 mM Tris buffer at pH 8.0. This was followed by a
10mL linear gradient to 0.25MNaCl in Tris buffer, and then by
a5mL linear gradient to 1MNaCl in Tris buffer.Most antibody-
reactiveMV-Neluted in the high salt fractionsbetween0.4 and
0.7 M NaCl. These fractions were pooled, concentrated using
a Centricon-30 centrifugal filter device (Millipore Corporation,
Bedford, MA), and exchanged into a buffer containing 10 mM
sodium phosphate with 0.85% NaCl at pH 7.2 (phosphate-
buffered saline [PBS]). Approximately 115 μg of protein was
recovered (BCA micro assay, Pierce, Rockford, IL). MonoQ
purifiedMV-Nwas coupled in a buffer containing 50mMMES
at pH5.0with 0.85%NaCl at a concentration of 6 μg of protein
per 1.25 × 107 beads in 1 mL final volume.
Cloning of the Plasmodium malariae MSP119 coding se-
quence from China I parasite strain is described else-
where.33 This antigen was coupled to 1.25 × 107 SeroMap
beads in 50 mM MES buffer at pH 5.0 with 0.85% NaCl at a
concentration of 30 μg/mL. The glutaraldehyde protocol of
Benitez et al.34 was used to cross-link a synthetic 20
amino acid peptide ([NANP]5-amide) corresponding to the
carboxy-terminal repeat of the P. falciparum circum-
sporozoite protein35,36 to purified GST protein. Bead cou-
pling conditions for this antigen were identical to those
described previously for the P. malariae MSP119 protein.
Purified native hemoglobin (Hb) from Ascaris suum worms
was a kind gift from P. Geldhof (Ghent University, Gent,
Belgium).37,38 This antigen was coupled to 1.25 × 107 Sero-
Map beads in a PBS buffer (pH 7.2) at a concentration of 120
μg/mL.
Multiplex bead assay. One bloodspot from each partici-
pant, corresponding toabout 10μLofwhole blood,waseluted
overnight at 4C with 200 mL of PBS containing 0.05%
Tween-20 and 0.05% sodium azide (1:40 serum dilution
assuming a 50% hematocrit). A further dilution of 50 mL of
eluate into 450 μL of PBS containing 0.5% casein, 0.3%
Tween-20, 0.02% sodium azide, 0.5% polyvinyl alcohol,
and 0.8% polyvinylpyrrolidone (designated as PBN1) with
3 μg/mL Escherichia coli extract was made for a final serum
dilution of 1:400. Serum dilutions were centrifuged at a
maximum speed to pellet any E. coli extract particulates
immediately before use. Bloodspot dilutions were assayed
in duplicate with antigen-coupled microsphere beads using
a Bio-Plex 200 instrument equipped with Bio-Plex Man-
ager 6.1 software (Bio-Rad, Hercules, CA), as previously
described.22,24,26 The average of the median fluorescent
intensity values from the duplicate wells minus the back-
ground fluorescence from the buffer-only blank was re-
ported as the “median fluorescence intensity minus
background” (MFI-bg). Samples having a coefficient of
variation of > 15% for ³ 2 positive responses between the
duplicate wells were repeated.
Cutoff determinations. The WHO International Standard
reference sera for tetanus (TE-3; 120 IU/mL) and diphtheria
(10/262; 2 IU/mL) purchased from the National Institute for
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Biological Standards and Control (NIBSC) (Potters Bar, Hert-
fordshire, United Kingdom) were used to identify MFI-bg cutoff
values corresponding to immunoprotection. A tetanus TE-3
value of 10mIU/mL39,40 corresponded to a tetanus toxoidMBA
response of 118 MFI-bg units. A diphtheria toxoid MBA re-
sponse of 4393 MFI-bg units corresponded to the 0.1 IU/mL
threshold for complete protection,41 and an MBA response of
183MFI-bg units corresponded to the 0.01 IU/mL threshold for
partial protection.Other studieshaveshowngoodconcordance
between the MBA and “gold standard” formats for tetanus and
diphtheria.32,42 Although aWHO reference standard is available
for the quantitation of measles virus–neutralizing antibody re-
sponses using the whole virus Plaque Reduction Neutralization
Test (PRNT) (NIBSC 97/648; 3 IU/mL), the standard has not
been calibrated for use in ELISA format assays43 and our MBA
only detects IgG antibodies to the measles MV-N protein. In an
independent work using the specific bead set from this study,
Coughlin et al. (in preparation)determined that receiver operator
characteristic (ROC)-optimizedMFI-bg cutoff value of 178MFI-
bg units provided good sensitivity and specificity compared
with the “gold standard” PRNT.
Multiplex bead assay cutoff estimates for the S. stercoralis
NIE assay and for the three LF antigens (Bm33, Bm14, and
Wb123) were assigned using a panel of 94 presumed negative
sera donatedby anonymous adult U.S. citizenswith no history
of foreign travel. Test values greater than the mean plus three
SDsof thepresumednegative sample valueswere considered
to be positive. For the P. malariae and P. falciparum MSP119
assays, log-transformed data were used for the mean plus
three SD calculation, and the panel used for the P. falciparum
cutoff included only 65 of the original 94 U.S. adult volunteers.
An ROC curve using sera from 41 stool-confirmed, anony-
mous ascariasis patients, 65 of the adult U.S. citizen volun-
teers, and sera from 45 anonymous U.S. children was used to
identify the cutoff for the Ascaris Hb MBA. All of the parasitic
disease cutoff valueswere adjusted to account for differences
between the instrument used for cutoff determination at the
CDC in Atlanta, GA, and the instrument used to assay the
Kenyan sample set at KEMRI in Nairobi, Kenya. Two-fold se-
rial dilutions of the same strong positive sera were assayed on
both instruments to generate standard curves for cutoff value
adjustment. Schistosoma mansoni SEA and Sm25 coupled
beads were used in an earlier study, and the adjusted, ROC-
assigned cutoff values have been reported elsewhere (965
and 38 MFI-bg units, respectively).30
We also estimated seropositivity cutoff points for malaria,
LF, and helminth antibody responses using the mean plus
three SDs of a seronegative distribution estimated from the
study measurements using finite Gaussian mixture models
with two components.44
Ethical considerations. The study received ethical ap-
proval fromKEMRI Scientific and Ethics ReviewUnit (SSCNo.
3018). In the study villages, chiefs and assistant chiefs
arranged for community mobilization meetings during which
the purpose of the survey and procedures to be followedwere
explained. Written informed consent was obtained from every
individual who agreed to participate in this study; parents or
legal guardians provided signed informed consent forms on
behalf of children younger than 18 years of age. The consent
information given to the study participants requested for fin-
gerprick blood to test for LF infection and additional DBS
specimen for testing of other common diseases in coastal
Kenya, including vaccine-preventable diseases. All the DBS
samples were transported to Nairobi and analyzed in the
KEMRI-ESACIPAC laboratory.
Statistical analysis. Mean antibody levels (expressed in
MFI-bg units) were analyzed on the log10 scale because of
skewness in their distribution. We estimated age-dependent
mean antibody levels and seroprevalence for each study
community using cross-validated, ensemble machine learn-
ing,with a library that included the simplemean, linearmodels,
locally weighted regression (loess), and smoothing splines
with 2 to 10 degrees of freedom, selected using 10-fold cross-
validation.18 We estimated age-adjusted geometric mean
antibody levels and seroprevalence for each community using
targetedmaximum likelihood estimation with influence curve-
based standard errors.18 In cases where seroprevalence
approached zero, we estimated exact binomial CIs. Analyses
were conducted using R version 3.3.1, and full replication files
(data and scripts) are available through the Open Science
Framework (https://osf.io/taknp).
RESULTS
Antibody measurements were obtained from 2,837 indi-
viduals (range 271–297 per community) (Supplemental
Figure 1). Antibody distributions varied by pathogen and an-
tigen, and seropositivity cutoff values for malaria, LF, and
helminth antibody responses derived through ROC curve
analysis ormean plus three SD calculationswere very close to
those derived by Gaussian mixture model analysis (Figure 1).
We therefore relied on cutoff values derived from the Gauss-
ian mixture model antibody responses for comparability to
future studies that may not have access to positive and neg-
ative control specimens. Age-dependent patterns and
community-level estimates of mean antibody levels and
seroprevalence were consistent in their age-dependent pat-
terns and in their community-level ranking (Supplemental
Figures 2–6), so we report results based on mean antibody
levels in supporting information.
Antifilarial antibody measurements. Individuals who
tested positive for LF infection by ICT had higher mean levels
of antibody responses against the three recombinant filarial
antigens (Supplemental Figure 7). Antibody seroprevalence
against all three recombinant filarial antigens were signifi-
cantly higher in Ndau Island than in other communities, and
the difference in seroprevalence in Ndau compared with other
communities was markedly greater among persons aged
less than 30 years (Figure 2). Antifilarial antibody responses
against Bm14 antigen continued to increase with age in all
communities. For Wb123, seroprevalence gradually in-
creased with age in Ndau and increased from around the age
of 30–35 years in Mwadimu community. Compared with the
other communities, Jaribuni had slightly elevated mean anti-
body responses against Wb123 and Bm33 antigens (P <
0.0001), but not for Bm14 antigen (P = 0.08). Among the
youngest children, quantitative antibody levels differentiated
communities more clearly than seroprevalence, owing to high
variability in seroprevalence estimates from the small sample
sizes in the youngest age strata (Supplemental Figure 8).
Antibody responses to other parasite antigens.Antibody
responses to the P. falciparum CSP and MSP-119 antigens
increased with age in communities in Kilifi and Kwale
counties, with higher seroprevalence in Jaribuni community
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FIGURE 1. Distribution of IgG antibody levels measured in 10 communities in Kenya’s coastal region, 2015. Antibody response measured in
multiplex using median fluorescence intensity minus background (MFI-bg) units on a BioRad Bio-Plex platform. Seroprotection cutoff points for
measles, diphtheria, and tetanus estimated using a standard curve from WHO reference standards. Seropositive cutoff points for other antigens
estimated using negative control serum samples (solid) and finite Gaussian mixture models (dashed). There was no negative control cutoff point
determined for thePlasmodium falciparumCSP antigen. Supplemental Table 1 includes cutoff values. Createdwith script: https://osf.io/d9jrc. This
figure appears in color at www.ajtmh.org.
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than in other communities in Kilifi (P < 0.0001, Figure 3). Mean
antibody responses against P. malariaeMSP-119 antigen also
increased with age and were highest in Jaribuni (P < 0.0001),
but very low inNdau IslandandKipini communities (P<0.0001
for difference with other communities).
Antibody responses againstS.mansoniSm25 recombinant
antigen were primarily detected in Kimorigo community in
Taita–Taveta County, and the seroprevalence increased
gradually with age, reaching a peak at around 25 years of
age (Figure 4). However, although antibody responses
to S. mansoni SEA antigen also increased with age in
Kimorigo community andmean seroprevalencewas higher,
there were some responses against this antigen in many
other communities. Compared with the Sm25 recombinant
antigen, the S. mansoni SEA antigen may have limited
application in serosurveillance surveys because of cross-
reactivity.
Steady increases in S. stercoralis NIE seroprevalence with
age were observed and community-level mean seropreva-
lence ranged between 3% and 26% (Figure 5). There was
heterogeneity in age-dependent Ascaris Hb seroprevalence
patterns across communities, with seroprevalence increasing
with age in some communities and decreasing with age in
others (Figure 5).
Immune responses to vaccine-preventable diseases.
Immune response against measles MV-N antigen increased
with age, but two communities in Kwale County (Mirihini and
Mwadimu) had < 90% seroprotection (Figure 6). Immune re-
sponses to diphtheria toxoid were relatively higher among
children but waned slightly around the ages of 30–40 years
FIGURE 2. Lymphatic filariasis antibody age-dependent seroprevalence and overall means, stratified by community in Kenya’s coastal region,
2015. Community-level mean seroprevalence is age-adjusted and error bars represent 95% CIs. Supplemental Figure 2 is an extended version of
this figure that also includes mean antibody levels. Created with script: https://osf.io/5zkxw. This figure appears in color at www.ajtmh.org.
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before increasing slightly. Generally, diphtheria seropro-
tection ranged between 22% and 44% across communi-
ties, and partial protection (defined as responses of
0.01–0.099 IU/mL) ranged between 70% and 88% across
communities. Immune responses against tetanus toxoid de-
creased by age in all communities until around 15 years when
the levels increased again. However, tetanus seroprotection
was lower in all three communities in Kwale County.
DISCUSSION
Antibodies can provide valuable information about expo-
sure to pathogens and can be helpful for characterizing
transmission dynamics in an area to help prioritize where and
what interventions may be considered.24,45 This study
provides an important proof of concept for how the value of
existing epidemiological surveillance activities could dramat-
ically be increasedusing small volumesofbloodcollectedona
filter paper and analyzed using a single multiplex laboratory
assay and novel data analysis techniques.
The LF survey in the coastal region of Kenya, which pro-
vided the opportunity to collect information for this study,
demonstrated that Ndau Island in Lamu County had the
highest prevalence of CFA by ICT.17 The antifilarial antibody
measurements assessed by theMBAplatform closely aligned
with the CFA results. Ndau Island had the highest levels
of antibody responses to all three recombinant filarial anti-
gens, which confirms the observation that LF transmission is
presently higher in Ndau Island than in the other communi-
ties. Previous studies have demonstrated a spatial relationship
FIGURE 3. Malarial antibody age-dependent seroprevalence and overall means, stratified by community in Kenya’s coastal region, 2015.
Community-level mean seroprevalence is age-adjusted and error bars represent 95% CIs. Supplemental Figure 3 is an extended version of this
figure that also includes mean antibody levels. Created with script: https://osf.io/kzfd3. This figure appears in color at www.ajtmh.org.
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between antibody-positive individuals and infected persons.46
The high seroprevalence rates in Ndau, especially among
children, are consistent with the conclusion that transmission
may be ongoing and not yet halted by the MDA campaign.
Antibody responses against Bm14 antigen continued to
increase with age in all villages, which may have been an in-
dication of cumulative exposure toW.bancrofti, and also likely
reflects historic transmission. Generally, antibody responses
against the three recombinant filarial antigens were higher
among CFA-positive individuals than among CFA-negative
persons although thedifferencewas relatively smaller forBm33
(see Supplemental Figure 7). Results from a recent study in
American Samoademonstrated that polymerase chain reaction-
positive pools of LF vector mosquitoes were statistically
significant predictors of seropositivity forWb123butnotBm14,
suggesting Wb123 could be an indicator of ongoing trans-
mission.47 Longitudinal studies in areas of intense LF trans-
mission have shown that children acquire infections early in
life.48,49 In addition, previous studies have demonstrated that
antibody response against infective-stage filarial larvae anti-
gen Wb123 is a specific measure of W. bancrofti infection,
and reduction in both antibody prevalence and transmission
is seenmost clearly in youngchildren.50,51Quantitative antifilarial
antibody responses among youngest children (aged 2–5 years
and 6–10 years) provided much higher resolution distinctions
between communities compared with seroprevalence using the
same antigens or the ICT test (Supplemental Figure 8)—a result
consistent with a recent analysis across diverse pathogens in
FIGURE 4. Schistosomiasis antibodyage-dependent seroprevalence andoverallmeans, stratifiedbycommunity inKenya’s coastal region, 2015.
Community-level mean seroprevalence is age-adjusted and error bars represent 95% CIs. Supplemental Figure 4 is an extended version of this
figure that also includes mean antibody levels. Created with script: https://osf.io/tpcg7. This figure appears in color at www.ajtmh.org.
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low-transmission settings where seropositive individuals are
rare.18 The higher resolution of quantitative antibody responses
compared with seroprevalence, particularly when measured in
small sampling clusters, suggests that quantitative antibody
levels couldserveasan important andmoresensitive indicatorof
recent exposure in sentinel populations of young children and
may be a valuable tool for surveillance in the context of LF
elimination programs.20 Thus, combined measurement of these
markers may be suitable for characterization of LF transmission
settings, particularly toward the end of the program when the
infection prevalence is very low.
There was high heterogeneity in malaria seroprevalence
among the study communities, with Kwale and Kilifi
counties generally showing relatively higher malaria trans-
mission than the other three counties. The communitymean
seroprevalence values suggested that both P. falciparum
and P. malariae transmission were highest in Jaribuni
community in Kilifi County. These differences may reflect
environmental heterogeneity in malaria larval breeding
sites, and Jaribuni may be a hot spot for malaria trans-
mission. A previous study in Kilifi and Kwale counties
identified the primary vectors of malaria along the coast of
Kenya to includeAnopheles funestus and threemembers of
the An. gambiae complex: An. gambiae s.s., An. arabiensis,
and An. merus.52 The study also showed that relatively
high malaria parasite prevalence can occur at low and even
FIGURE 5. Age-dependent seroprevalence and overall mean for antibodies toStrongyloides stercoralis andAscaris spp. stratified by community
inKenya’scoastal region, 2015.Community-levelmeanseroprevalence is age-adjustedanderror bars represent 95%CIs. Supplemental Figure 5 is
an extended version of this figure that also includes mean antibody levels. Created with script: https://osf.io/j7ux3. This figure appears in color at
www.ajtmh.org.
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non-detectable levels of entomological inoculation rates
(EIR), suggesting that measurement of EIR may be a rela-
tively insensitive indicator of malaria transmission in some
settings. Although malaria parasite prevalence and/or EIR
have traditionally been used for reporting malaria trans-
mission intensity,53 serological markers have increasingly
been recognized as useful indicators for estimating malaria
transmission intensity, which is key for assessing the im-
pact of control interventions.54–57 Because of the longevity
of the specific antibody response, seroprevalence reflects
cumulative exposure and, thus, is less affected by sea-
sonality or unstable transmission.58
In Kenya, Schistosoma haematobium is highly endemic
along the coast where human exposure occurs primarily at
pond and stream snail habitats.9,59,60 The absence of
S. mansoni from most of the Kenyan coastal region is attrib-
utable to the absence of the Biomphalaria spp. intermediate-
host snails.61 InMikinduni community, along the lower Tana
River, crude antigen SEA antibody responses were ob-
served, but S. mansoni–specific Sm25 responses were
lacking. By contrast, Taveta area in Taita–Taveta County is
known to be endemic for both S. haematobium and
S. mansoni infections,62,63 and this is reflected in the high
SEA and Sm25 antibody responses we observed in
Kimorigo, a community located on the banks of the shal-
low freshwater Lake Jipe. The absence of S. mansoni
species–specific antibody responses to Sm25 recombinant
antigen in all of the communities except Kimorigo confirms
FIGURE 6. Age-dependent seroprotection and overall seroprotection for measles, diphtheria, and tetanus stratified by community in Kenya’s
coastal region, 2015. Community-level seroprotection is age-adjusted and error bars represent 95% CIs. For diphtheria, we included sepa-
rate community-level estimates of seroprotection (MFI-bg > 4,393 corresponding to 0.1 IU/mL) and partial protection (MFI-bg > 183 corresponding
to0.01 IU/mL).Supplemental Figure6 is anextendedversionof thisfigure that also includesmeanantibody levels.Createdwith script: https://osf.io/
qrkhm. This figure appears in color at www.ajtmh.org.
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that S. mansoni infection is likely absent from the lower
coastal areas. Thus, S. mansoni Sm25 recombinant antigen
seems to be an excellent antigen for measuring antibody
responses to S. mansoni infection,64 and SEA antigen likely
detects antibody responses caused by both Schistosoma
species by virtue of cross-reactivity.
The presence of responses to S. stercoralis NIE antigen is
noteworthy because there has been little information on the
geographic distribution of this helminth in Kenya due to di-
agnostic limitations. Copromicroscopic diagnostic meth-
ods commonly used in soil-transmitted helminthiasis
prevalence studies are inadequate for S. stercoralis de-
tection,65 and thus its distribution in many areas is un-
known. Concentration methods, namely, the Baermann
technique and Koga agar plate culture, have better
but still unsatisfactory sensitivity.66 A study using NIE se-
rology in Argentina found no cross-reactivity between
S. stercoralis and infections with A. lumbricoides, hook-
worms, or Hymenolepis nana, and the presence of other hel-
minths in the stool did not affect the S. stercoralis–specific
antibody responses.67 A study comparing five serologic tests
identified NIE–luciferase immunoprecipitation system to be the
most accurate assay for the diagnosis of S. stercoralis in-
fection.68 Previous studies using the recombinant NIE have
documented high seroprevalence of S. stercoralis infection in
remote Australian Indigenous communities and suggest that
collection of DBSs may be a useful approach for field diagno-
sis of S. stercoralis seroprevalence.69,70 This study, therefore,
provides evidence for possible low-level transmission of
S. stercoralis in coastalKenyaas theseroprevalencevaries from
community to community. Community mean antibody re-
sponses to the Ascaris Hb native antigen and seroprevalence
exhibited high heterogeneity among the study communities. A
population-based study in Indonesia has shown that an assay
for antibodies toAscarisHb is useful for assessing transmission
ofAscaris infections, and community antibody rates decreased
rapidly following MDA of anthelmintic drugs. The decrease
was also found to reflect reduced egg excretion at the com-
munity level.38
Vaccination is one of the most cost-effective public health
interventions available, and the epidemiology and burden of
VPDs vary by country and by region partly because of dif-
ferences in vaccine uptake.71 This multiplex-integrated
serosurveillance study identified heterogeneity in serologic
antibody levels against measles, diphtheria, and tetanus
antigens. Our study demonstrates a need for regularly
monitoring serological responses to vaccination programs
in resource-poor settings where coverage may be low.
Someof the limitations of this study are somewhat similar to
those highlighted previously.24 This was a preliminary, proof-
of-concept study, and, because of the lack of direct com-
parison of results with those obtained from already validated
commercial assays, theMBAdescribedherewasnot intended
to replace diagnostic tests that are presently available for use
by disease control/elimination programs. Also, serological
studies are traditionally faced with the challenge of estab-
lishing diagnostic cutoff points, especially when well-
characterized positive and negative serum samples are not
available. Nonetheless, the Gaussian mixture models applied
in this study led to cutoff values that were very similar to those
derived through ROC curves or from mean plus three SD
calculations for malaria, LF, and helminth antibody responses
(Figure 1). This result is consistent with a recent, multicountry
comparison of cutoff methodology for trachoma antibodies72
and supports the use of finite mixture models to identify se-
ropositivity cutoffs in studies without access to panels of
known positive and negative specimens. For pathogens
where cutoff values fall in the center of a unimodal distribution
and it is more difficult to distinguish seropositive and sero-
negative groups (e.g., A. suum Hb in Figure 1), the use of
community mean antibody levels avoids the requirement of
choosing a cutoff, and observed antibody response patterns
were very consistent with seroprevalence estimates across all
of the antibodies tested in this study (Supplemental Figures
2–6). Another limitation of this study is potential for helminth
antibody cross-reactivity, particularly because the MBA
measured total IgG antibody rather than the more specific
IgG4.Because the coastal area has a typical tropical climate, it
is likely that a plethora of pathogens are coincident, somewith
potentially cross-reactive antigens. A previous study reported
that cross-reactivity of the Ascaris Hb native antigen with
hookworm and possibly S. stercoralis and Toxocara spp.
limited its value in serology if one is interested in ascariasis
alone.38 Thus, further studies are required to identify sensitive
and specific recombinant antigens that could be used with
more confidence in serological assays. A final limitation is that
the multiplex assay we used in our study is not commercially
available. In practice, it will be more realistic for programs to
incorporate integrated antibody surveillance into their surveys
when bead-based antibody assays can be purchased in a
ready-to-use kit format, especially if the assays can be ana-
lyzed with instruments that do not rely on flow cytometry for
fluorescent signal detection. Commercial kits with good
quality control would potentially also help standardize the
assays across laboratories.
Despite these limitations, this study successfully used a
single multiplex-integrated serological assay and analysis
methodology to measure antibody levels against several
pathogens. Therewasnoneed to run separate assays for each
pathogen, and we did not need to develop different mathe-
matical models for each pathogen to compare exposure
across communities and counties. The study highlighted
overlap in pathogen burden that would not necessarily have
been detected through single-disease surveillance. For ex-
ample, Ndau Island was found to have not only the highest LF
seroprevalence but also highest Ascaris seroprevalence, thus
supporting integrated control of these two helminths. In-
terestingly, Ndau had almost no evidence for P. falciparum
malaria transmission. On the other hand, Jaribuni commu-
nity was found to stand out in terms of malaria, LF, and
Strongyloides. Multiplex serosurveillance has the potential
to enable us to look across diseases for opportunities for
integrated control, thus providing synergy to global public
health initiatives.
CONCLUSION
This study highlighted the utility of the MBA platform for
integrated serosurveillance of biomarkers of diseases of
public health importance. The multiplex-integrated serologic
assay has the potential to become an invaluable comple-
mentary epidemiologic tool for integratedmonitoring of trends
in endemicity of diseases of public health importance and the
effectiveness of public health control programs.
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